Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence-Reference-Cited by-同舟云学术

Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence

Published:2011-06-06 Issue:1 Volume:4 Page:
ISSN:1756-0500
Container-title:BMC Research Notes
language:en
Short-container-title:BMC Res Notes

Author:

Namujju Proscovia B,Hedman Lea,Hedman Klaus,Banura Cecily,Mbidde Edward K,Kizito Dennison,Byaruhanga Romano N,Muwanga Moses,Kirnbauer Reinhard,Surcel Heljä-Marja,Lehtinen Matti

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/1756-0500-4-170.pdf

Reference31 articles.

1. Ferlay J, Bray F, Pisani P, Parkin MD: GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base. 2004, IARC, Lyon, 2.0

2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999, 189: 12-9. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.

3. Ho GY, Studentsov Y, Bierman R, Beardsley L, Lempa M, Burk RD: Risk factors subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus like particles. J Infect Dis. 2002, 186: 737-42. 10.1086/342972.

4. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan ET, Ferenczy A, Villa LL, Franco EL: Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1274-80. 10.1158/1055-9965.EPI-06-0129.

5. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009, 199: 926-35. 10.1086/597307.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Seroepidemiological survey on sporotrichosis-infection in rural areas of the south of Minas Gerais State, Brazil;Brazilian Journal of Microbiology;2020-05-13

2. HPV vaccines: how many doses are needed for protection?;Future Virology;2016-04

3. Immune memory responses to HBV vaccine 13-18 years after primary vaccination;Genetics and Molecular Research;2015

4. Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study;BMC Research Notes;2014-07-11

5. Immune memory response induced in vitro by recombinant hepatitis B surface antigen challenge 13-18 years after primary vaccination;Journal of Medical Virology;2014-07-05